U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT07491172) titled 'A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias' on March 18.
Brief Summary: This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refractory to available treatments.
Study Start Date: June 21, 2024
Study Type: INTERVENTIONAL
Condition:
Cardiovascular
Metabolic Disease
Dyslipidemias
Lipid Disorder
Hypertriglyceridemia
Heterozygous Familial Hypercholesterolemia (HeFH)
Homozygous Familial Hypercholesterolemia (HoFH)
Severe Hypertriglyceridemia (sHTG)
Mixed Hyperlipemia
Hypercholeste...